Glycated Hemoglobin as a Dual Biomarker in Type 2 Diabetes Mellitus Predicting Glycemic Control and Dyslipidemia Risk

Diabetes mellitus is associated with hyperglycemia and patients are at an increased risk of cardiovascular disease. The present study was carried out to evaluate the diagnostic value of Glycated hemoglobin (HbA1c) in predicting risk of development of diabetic dyslipidemia. 70 clinically diagnosed cases of type 2 diabetes mellitus with the age range 30-75 years were included in the study group. Out of which 35 diabetic patients with good glycemic control were included under Group A and 35 diabetic patients with poor glycemic control were included under Group B. 70 age and sex matched healthy individuals served as controls. HbA1c demonstrated positive and significant correlation with total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and LDL/HDL-C, non-HDL-C and TC/HDL-C ratio. Patients with HbA1c value > 7.0% had significantly higher value of TC, Triacylglycerol (TAG), LDL-C, LDL-C/HDL-C ratio, non-HDL-C and TC/HDL-C ratio as compared to the patients with HbA1c ≤ 7.0%. However, there was no significant difference in value of HDL-C between two groups. Thus HbA1c can be used as a potential dual marker of glycemic control and dyslipidemia in type 2 diabetes mellitus.